Artificial intelligence applications in rare and intractable diseases: Advances, challenges, and future directions

Karako K

Intractable Rare Dis Res. 2025; 14(2):88-92.

DOI: 10.5582/irdr.2025.01030

Frailty in older adults: A systematic review of risk factors and early intervention pathways

Deng Y, Yamauchi K, Song PP, Karako T

Intractable Rare Dis Res. 2025; 14(2):93-108.

DOI: 10.5582/irdr.2025.01026

Traditional Chinese medicine for intractable and rare diseases: Research progress and future strategies

Liu YZ, Ren YM, Song PP

Intractable Rare Dis Res. 2025; 14(2):109-121.

DOI: 10.5582/irdr.2025.01028

Evaluation of pharmacotherapy in sickle cell disease in an Afro-Colombian community: A cross-sectional analytical study in San Basilio de Palenque, Bolívar

Ahumada L, Alviz A, Gonzalez T, Gomez G

Intractable Rare Dis Res. 2025; 14(2):122-127.

DOI: 10.5582/irdr.2025.01007

Clinical and genetic analysis of ulnar-mammary syndrome caused by a novel TBX3 mutation in a Chinese boy

Yang JM, Yu HM, Sun Y, Chen C, Li GM, Xu C

Intractable Rare Dis Res. 2025; 14(2):128-134.

DOI: 10.5582/irdr.2024.01078

Pathonign variants in recessive disorders: How extremely hypomorphic variants can be pathogenic and benign depending on the allele in trans

Fabre A, Guerry P

Intractable Rare Dis Res. 2025; 14(2):135-137.

DOI: 10.5582/irdr.2025.01014

Precision grading of surgical strategies for small bowel Crohn's disease: An R0–R3 individualized framework based on lesion severity and functional preservation

Yang LC, Jiang ZX, Sun Q, Yuan LW

Intractable Rare Dis Res. 2025; 14(2):138-142.

DOI: 10.5582/irdr.2025.01027

Vimseltinib: A novel colony stimulating factor 1 receptor (CSF1R) inhibitor approved for treatment of tenosynovial giant cell tumors (TGCTs)

Dou FZ, Lu DR, Gao JJ

Intractable Rare Dis Res. 2025; 14(2):143-144.

DOI: 10.5582/irdr.2025.01010

Primary rectal malignant melanoma with schistosomiasis

Cheng ZM, Wang C, Cai YL

Intractable Rare Dis Res. 2025; 14(2):145-147.

DOI: 10.5582/irdr.2025.01018

A case of mitochondrial diabetes mellitus with successful therapeutic response following the initiation of imeglimin

Ishimura A, Suzuki S

Intractable Rare Dis Res. 2025; 14(2):148-150.

DOI: 10.5582/irdr.2025.01019